financetom
Business
financetom
/
Business
/
Update: Erie Indemnity Shares Face Up to 55% Potential Downside Risk, Spruce Point Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Erie Indemnity Shares Face Up to 55% Potential Downside Risk, Spruce Point Says
Oct 18, 2024 9:28 AM

11:59 AM EDT, 10/18/2024 (MT Newswires) -- (Updates with Erie's response in the fourth and fifth paragraphs.)

Erie Indemnity ( ERIE ) shares face a potential downside risk of 35% to 55% amid concerns about the sustainability of its 25% management fee collected on Erie Insurance Exchange-written premiums, short seller Spruce Point Capital Management said Friday.

"Given the recent deterioration of the Exchange's financial performance... we believe it is increasingly likely that Erie's management fee will decline for the first time in decades which could reset earnings expectations by approximately 20% and slow premium growth at the Exchange over the coming years," Spruce Point said.

Spruce Point added that aside from the possibility of an impending management fee cut, it has other concerns with the company, such as AM Best's revision of its outlook for Erie Insurance Group's members to negative from stable in August.

Matthew Cummings of Erie Insurance told MT Newswires that the company continues to be confident in its financial strength.

"Our impressive growth and industry leading customer retention serve as a testament to the service and stability that has set us apart for nearly 100 years," Cummings said. "We're pleased with the success we've achieved and the strong value proposition we continue to offer agents, customers, employees and the communities we serve."

Price: 483.95, Change: +0.90, Percent Change: +0.19

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review
GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review
Apr 16, 2024
08:14 AM EDT, 04/16/2024 (MT Newswires) -- GSK (GSK) said in a regulatory filing Tuesday that the US Food and Drug Administration has accepted for review the company's biologics license application for its meningococcal ABCWY vaccine candidate. The pharmaceutical giant said the vaccine candidate provides broad coverage against the five most common groups of bacteria causing invasive meningococcal disease, and...
Vizsla Silver Down 2.1% in US Premarket as Agrees to Buy Claims Near Panuco Project in Mexico
Vizsla Silver Down 2.1% in US Premarket as Agrees to Buy Claims Near Panuco Project in Mexico
Apr 16, 2024
08:23 AM EDT, 04/16/2024 (MT Newswires) -- Vizsla Silver ( VZLA ) was at last look down 2.1% in US premarket on Tuesday after agreeing to acquire two large claims located south and partially adjacent to the company's Panuco project in Mexico. The just-acquired San Enrique prospect, which is almost 50% larger than Panuco, is located along the highly prospective...
TELUS International Up 1% In US Premarket As It Expands Partnership With Nasdaq-listed Appian
TELUS International Up 1% In US Premarket As It Expands Partnership With Nasdaq-listed Appian
Apr 16, 2024
08:18 AM EDT, 04/16/2024 (MT Newswires) -- TELUS International , a digital customer experience (CX) innovator, was at last look up 1% in US premarket after saying Tuesday that it has expanded its partnership with Appian to help clients accelerate business processes and application development via intelligent automation as a service (AaaS) platform that incorporates Appian's low-code application development capabilities....
Foghorn Therapeutics Names Kristian Humer CFO
Foghorn Therapeutics Names Kristian Humer CFO
Apr 16, 2024
08:16 AM EDT, 04/16/2024 (MT Newswires) -- Foghorn Therapeutics ( FHTX ) said Tuesday that Kristian Humer has been named chief financial officer, effective immediately. Humer most recently served as CFO and chief business officer at Viridian Therapeutics ( VRDN ) , the company said. ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved